Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

NEXT STORY
Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
PREV STORY
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline

author_avatar
NASDAQ Market News

Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

author_avatar
NASDAQ Market News

Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting

MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...

author_avatar
NASDAQ Market News